Literature DB >> 11028487

The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy.

P Dorian1, W Jung, D Newman, M Paquette, K Wood, G M Ayers, J Camm, M Akhtar, B Luderitz.   

Abstract

OBJECTIVES: We sought to assess the impact of intermittent atrial fibrillation (AF) on health-related quality of life (QoL).
BACKGROUND: Intermittent AF is a common condition with little data on health-related QoL questionnaires to guide investigational therapies.
METHODS: Outpatients from four centers, with documented AF (n = 152), completed validated QoL questionnaires (Medical Outcomes Study Short Form 36 [SF-36], Specific Activity, Symptom Checklist, Illness Intrusiveness and University of Toronto AF Severity Scales). Comparison groups were made up of healthy individuals (n = 47) and four cardiac control groups: published (n = 78) and created for study (n = 69) percutaneous transluminal coronary angioplasty (PTCA); published heart failure (n = 216) and published postmyocardial infarction (MI) (n = 107).
RESULTS: Across all domains of the SF-36, AF patients reported substantially worse QoL than healthy controls (1.3 to 2.0 standard deviation units), with scores of 24%, 23%, 16% and 30% lower than healthy individuals on measures of physical and social functioning, mental and general health, respectively (all p < 0.001). Patients with AF were either significantly worse (p < 0.05, published controls) or as impaired (study controls) as either PTCA or post-MI patients on all domains of the SF-36 and the same as heart failure controls on SF-36 psychological subscales. Patients with AF were as impaired or worse than study PTCA controls on measures of illness intrusiveness, activity limitations and symptoms. Associations between objective disease indexes and subjective QoL measures had poor correlations and accounted for <6% of the total variability in QoL scores.
CONCLUSIONS: Quality of life is as impaired in patients with intermittent AF as in patients with significant structural heart disease. Patients' perception of QoL is not dependent on the objective measures of disease severity that are usually employed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028487     DOI: 10.1016/s0735-1097(00)00886-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  141 in total

1.  Automatic atrial anti-tachy pacing for the termination of spontaneous atrial tachyarrhythmias: clinical experience with a novel dual-chamber pacemaker.

Authors:  D Vollmann; J Stevens; A B Buchwald; C Unterberg
Journal:  J Interv Card Electrophysiol       Date:  2001-12       Impact factor: 1.900

Review 2.  Chemical transmitter systems in the brain.

Authors:  C C Shute
Journal:  Mod Trends Neurol       Date:  1975

3.  Point-by-point pulmonary vein antrum isolation guided by intracardiac echocardiography and 3D mapping and duty-cycled multipolar AF ablation: effect of multipolar ablation on procedure duration and fluoroscopy time.

Authors:  Yaariv Khaykin; Lauren Zarnett; Daniel Friedlander; Zaev A Wulffhart; Bonnie Whaley; David Giewercer; Bernice Tsang; Atul Verma
Journal:  J Interv Card Electrophysiol       Date:  2012-03-11       Impact factor: 1.900

Review 4.  Promise of factor Xa inhibition in atrial fibrillation.

Authors:  Sana M Al-Khatib; John H Alexander; Renato D Lopes; Kenneth W Mahaffey; Manesh R Patel; Christopher B Granger
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

Review 5.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

6.  Depression, anxiety, and quality of life after catheter ablation in patients with paroxysmal atrial fibrillation.

Authors:  Cai-Hua Sang; Ke Chen; Xue-Feng Pang; Jian-Zeng Dong; Xin Du; Hui Ma; Ji-Hong Liu; Chang-Sheng Ma; Ying-Xian Sun
Journal:  Clin Cardiol       Date:  2012-07-09       Impact factor: 2.882

7.  Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation?

Authors:  James P Daubert; Geoffrey S Pitt
Journal:  J Am Coll Cardiol       Date:  2012-06-20       Impact factor: 24.094

8.  Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF.

Authors:  Benjamin A Steinberg; DaJuanicia N Holmes; Karen Pieper; Larry A Allen; Paul S Chan; Michael D Ezekowitz; James V Freeman; Gregg C Fonarow; Bernard J Gersh; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-04-16

9.  Long-term outcomes (>2 years) of atrial fibrillation ablation using a multi-electrode ablation catheter in patients with paroxysmal atrial fibrillation.

Authors:  Khang-Li Looi; Parag Gajendragadkar; Tamer Taha; Maros Elsik; Elizabeth Scully; Patrick Heck; Simon Fynn; Munmohan Virdee; David Begley
Journal:  J Interv Card Electrophysiol       Date:  2012-10-25       Impact factor: 1.900

10.  Safety and feasibility of combined atrial fibrillation ablation and left atrial appendage occlusion after left atrial appendage electrical isolation.

Authors:  Kenneth Kita; Steven Carlson; Mary Huntsinger; Han Tun; Jina Sohn; Rahul N Doshi
Journal:  J Interv Card Electrophysiol       Date:  2019-08-03       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.